Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kaliman

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Prostaglandins, Leukotrienes, and Medicine|August 1, 1987
Prostacyclin synthesis stimulating plasma factor in patients with peripheral vascular diseaseE Strobl-Jäger, P Fitscha, J Kaliman, et al.
Prostaglandins, Leukotrienes, and Medicine|May 1, 1986
Prostacyclin synthesis stimulating plasma factor in patients with primary hyperlipoproteinemia--effect of dietary and drug treatmentH Sinzinger, J Kaliman, E Strobl-Jäger, et al.
Acta Medica Austriaca|January 1, 1984
[Diagnosis of syncopes in suspected arrhythmias]H Weber, C Müller, H Kiss, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|December 1, 1989
Beneficial effect of long-term PGE1-treatment in left ventricular heart failureI Virgolini, J Kaliman, P Fitscha, et al.
Prostaglandins|June 1, 1987
Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivoH Sinzinger, T Zidek, P Fitscha, et al.
Pediatric Cardiology|January 1, 1987
Exercise testing after surgical repair of coarctation of the aortaU Salzer-Muhar, J Kaliman, M Wimmer, et al.
Hormone and Metabolic Research. Supplement Series|January 1, 1981
Vascular prostacyclin, platelet sensitivity to prostaglandins and platelet-specific proteins in diabetes mellitus. Analysis of type of diabetes, state of metabolic control and diabetic microangiopathyG Schernthaner, H Sinzinger, K Silberbauer, et al.
Pacing and Clinical Electrophysiology : PACE|November 1, 1984
Reversible end-of-life indicator leading to erroneous pacemaker replacement-pitfalls of telemetryW Scheibelhofer, J Kaliman, H Mayr, et al.
Pacing and Clinical Electrophysiology : PACE|July 1, 1983
Reversible EOL-indicator: a new cause for low pacemaker rateW Scheibelhofer, J Kaliman, A Laczkovics, et al.
Experimental Pathology|January 1, 1990
Additive benefit of PGI2 and PGE1 (via different mechanisms?) on inhibition of activation of human vascular smooth muscle cells?H Sinzinger, P Fitscha, O Wagner, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Prostaglandins, Leukotrienes, and Medicine|August 1, 1987
Prostacyclin synthesis stimulating plasma factor in patients with peripheral vascular diseaseE Strobl-Jäger, P Fitscha, J Kaliman, et al.
Prostaglandins, Leukotrienes, and Medicine|May 1, 1986
Prostacyclin synthesis stimulating plasma factor in patients with primary hyperlipoproteinemia--effect of dietary and drug treatmentH Sinzinger, J Kaliman, E Strobl-Jäger, et al.
Acta Medica Austriaca|January 1, 1984
[Diagnosis of syncopes in suspected arrhythmias]H Weber, C Müller, H Kiss, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|December 1, 1989
Beneficial effect of long-term PGE1-treatment in left ventricular heart failureI Virgolini, J Kaliman, P Fitscha, et al.
Prostaglandins|June 1, 1987
Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivoH Sinzinger, T Zidek, P Fitscha, et al.
Pediatric Cardiology|January 1, 1987
Exercise testing after surgical repair of coarctation of the aortaU Salzer-Muhar, J Kaliman, M Wimmer, et al.
Hormone and Metabolic Research. Supplement Series|January 1, 1981
Vascular prostacyclin, platelet sensitivity to prostaglandins and platelet-specific proteins in diabetes mellitus. Analysis of type of diabetes, state of metabolic control and diabetic microangiopathyG Schernthaner, H Sinzinger, K Silberbauer, et al.
Pacing and Clinical Electrophysiology : PACE|November 1, 1984
Reversible end-of-life indicator leading to erroneous pacemaker replacement-pitfalls of telemetryW Scheibelhofer, J Kaliman, H Mayr, et al.
Pacing and Clinical Electrophysiology : PACE|July 1, 1983
Reversible EOL-indicator: a new cause for low pacemaker rateW Scheibelhofer, J Kaliman, A Laczkovics, et al.
Experimental Pathology|January 1, 1990
Additive benefit of PGI2 and PGE1 (via different mechanisms?) on inhibition of activation of human vascular smooth muscle cells?H Sinzinger, P Fitscha, O Wagner, et al.
Pageof 10